Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11241845 | PMC |
| http://dx.doi.org/10.1186/s12885-024-12600-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correction: Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in recurrent/metastatic nasopharyngeal carcinoma.
Br J Cancer
August 2025
State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Erratum: Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma.
Transl Cancer Res
June 2025
[This corrects the article DOI: 10.21037/tcr.2019.
View Article and Find Full Text PDFThe safety and effectiveness of sintilimab versus camrelizumab, both plus targeted drugs, in advanced hepatocellular carcinoma.
Front Immunol
July 2025
Department of Pharmacy, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, School of Clinical Medicine, Henan University, Zhengzhou, Henan, China.
Objectives: We aimed to evaluate the effectiveness and safety of sintilimab versus camrelizumab, both plus targeted drugs, for advanced hepatocellular carcinoma (HCC) in the real world. Then the effectiveness was compared between sintilimab-lenvatinib and camrelizumab-apatinib.
Methods: Patients diagnosed as advanced HCC were included from January 2017 to December 2023.
Erratum: Tumor cavitation in patients with non-small-cell lung cancer receiving anti-angiogenic therapy with apatinib.
Transl Lung Cancer Res
February 2025
[This corrects the article DOI: 10.21037/tlcr-24-465.].
View Article and Find Full Text PDFCorrigendum: Case report: Long remission and survival following immunotherapy in a case of pulmonary pleomorphic carcinoma.
Front Immunol
December 2024
Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, ;China.
[This corrects the article DOI: 10.3389/fimmu.2024.
View Article and Find Full Text PDF